Company Overview

Update
Founded:
2006
Headquarters:
San Diego, CA
Funding:
$22.6M
Categories:
Biotechnology
Description:
MabVax is a biopharmaceutical company focused on the commercialization of proprietary anti-cancer immunotherapies.

Detailed Description

Update

MabVax is a clinical stage biopharmaceutical company focused on the commercialization of proprietary anti-cancer immunotherapies resulting from two integrated and successful technology platforms. The first is a series of vaccines developed at Memorial Sloan-Kettering Cancer Center (MSKCC) and licensed to MabVax. Two of the company’s lead cancer vaccines are currently undergoing proof of concept Phase II multi-center clinical trials for the treatment of soft tissue sarcoma and ovarian cancer. Both trials have received $2MM or more in federal grant monies. The second is a human antibody discovery platform developed internally and based on the protective immune responses generated from patients who have been successfully immunized against targeted cancers with the licensed vaccines. The company’s lead human antibody candidate is undergoing preclinical evaluation for development against colon, pancreatic and breast cancers and has received $1.1MM in federal grant monies.

Current Team (3)

Update

Funding Rounds (5) - $22.6M

Update

Board Members and Advisors (1)

Update

Investors (3)

Update

Offices/Locations (1)

Update
  • Office

    11588 Sorrento Valley Road, Suite 20

    San Diego, CA 92121

    USA

Images (1)

Update
  • 1ce810e3e68b51100ad626a3120ac2da